Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 350 points on Thursday. The Dow traded down 0.70% to 51,153.35 while the NASDAQ dipped 0.70% to 26,746.39. The S&P 500 also fell, dropping, 0.46% to 7,670.50. Leading and Lagging Sectors Energy shares jumped by 1.7% on Thursday. In trading on Thursday, materials stocks fell by 1.1%. Top Headline Darden Restaurants Inc (NYSE: DRI ) reported worse-than-expected first-quarter financial results. Darden reported quarterly earnings of $2.05 per share which missed the analyst consensus estimate of $2.06 per share. The company reported quarterly sales of $3.200 billion which missed the analyst consensus estimate of $3.206 billion. Equities Trading UP Apimeds Pharmaceuticals US Inc ( NYSE: APUS ) shares shot up 163% to $6.02 after the company announced its subsidiary, MindWave, signed a 12-month technology services agreement with AQUAE Holdings to deploy its MindChain infrastructure as the foundation of AQUAEChain. Shares of Surrozen Inc (NASDAQ: SRZN ) got a boost, surging 90% to $30.63. Surrozen recently announced submission of IND application for SZN-8141 for the treatment of diabetic macular edema.
S. stocks traded lower midway through trading, with the Dow Jones index falling around 350 points on Thursday. 39. 50.
7% on Thursday. 1%. Top Headline Darden Restaurants Inc (NYSE: DRI ) reported worse-than-expected first-quarter financial results. 06 per share.
206 billion. 02 after the company announced its subsidiary, MindWave, signed a 12-month technology services agreement with AQUAE Holdings to deploy its MindChain infrastructure as the foundation of AQUAEChain. 63. Surrozen recently announced submission of IND application for SZN-8141 for the treatment of diabetic macular edema.
84 after the data storage company outlined a broader growth strategy and issued a preliminary fiscal 2028 outlook at its 2026 Financial Analyst Meeting. 20 after the company reported mixed fourth-quarter financial results and issued weak fiscal 2027 sales guidance. 82 after the company disclosed Phase 3 enabling topline results from Phase 2 RADIANT study of remlifanserin for the treatment of Alzheimer’s disease psychosis. 99 after the company announced a pair of proposed public offerings.
70. 7540. Euro zone European shares were mixed today. 1%.
67%. S. 6 billion gap in the previous quarter, versus market estimates of a $255 billion gap. S.
initial jobless claims fell by 1,000 to 197,000 in the second week of September, compared to market estimates of 201,000. S. 7% decline. Photo via Shutterstock